PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, 1 St. Kiriakidi Street, 54636, ThessalonĂ­ki, Greece.\', \'Cardiology Department, St.Thomas\' Hospital, London, UK.\', \'Infectious Diseases Division, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, ThessalonĂ­ki, Greece.\', \'Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, 1 St. Kiriakidi Street, 54636, ThessalonĂ­ki, Greece. kalmanthou@yahoo.gr.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1007/s11096-021-01256-9
?:doi
?:hasPublicationType
?:journal
  • International journal of clinical pharmacy
is ?:pmid of
?:pmid
?:pmid
  • 33751323
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.702
?:rankingScore_hIndex
  • 51
?:title
  • Sodium-glucose co-transporter 2 inhibitors in COVID-19: meeting at the crossroads between heart, diabetes and infectious diseases.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all